Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051987 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00051987 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 175 participants.
The verdict
NCT00051987, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and your cancer.
Interventions
- DRUG VELCADE TM (bortezomib) for Injection, or PS-341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051987
The ClinicalTrials.gov registry entry for NCT00051987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VELCADE TM (bortezomib) for Injection, or PS-341 is the first listed.
NCT00051987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051987 about?
NCT00051987 is a clinical study titled "Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma". The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and your cancer.
What is the current status of trial NCT00051987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2002-12.
What interventions are being tested in trial NCT00051987?
The interventions under investigation include: VELCADE TM (bortezomib) for Injection, or PS-341 (DRUG).
Who is sponsoring clinical trial NCT00051987?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.